Versartis Company Profile (NASDAQ:VSAR)

About Versartis (NASDAQ:VSAR)

Versartis logoVersartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company's first indication for somavaratan is pediatric GHD. The Company may develop somavaratan for additional growth disorders, such as idiopathic short stature (ISS), small for gestational age (SGA) and Turner Syndrome. Somavaratan is engineered using XTEN technology to extend the residence time in the bloodstream by reducing the clearance of recombinant human growth hormone (rhGH) from the body by the two primary mechanisms, kidney filtration and receptor mediated clearance.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VSAR
  • CUSIP: N/A
  • Web:
  • Market Cap: $575.65 million
  • Outstanding Shares: 35,208,000
Average Prices:
  • 50 Day Moving Avg: $19.03
  • 200 Day Moving Avg: $16.51
  • 52 Week Range: $7.87 - $24.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.80
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.60 per share
  • Price / Book: 4.54
  • EBIDTA: ($101,660,000.00)
  • Return on Equity: -64.93%
  • Return on Assets: -56.92%
  • Current Ratio: 3.02%
  • Quick Ratio: 3.02%
  • Average Volume: 318,492 shs.
  • Beta: 2.35
  • Short Ratio: 2.35

Frequently Asked Questions for Versartis (NASDAQ:VSAR)

What is Versartis' stock symbol?

Versartis trades on the NASDAQ under the ticker symbol "VSAR."

How were Versartis' earnings last quarter?

Versartis Inc (NASDAQ:VSAR) posted its quarterly earnings results on Thursday, April, 27th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.71) by $0.14. View Versartis' Earnings History.

When will Versartis make its next earnings announcement?

Versartis is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Versartis.

Where is Versartis' stock going? Where will Versartis' stock price be in 2017?

7 brokers have issued 12 month price objectives for Versartis' shares. Their predictions range from $20.00 to $34.00. On average, they anticipate Versartis' share price to reach $26.29 in the next year. View Analyst Ratings for Versartis.

What are analysts saying about Versartis stock?

Here are some recent quotes from research analysts about Versartis stock:

  • 1. According to Zacks Investment Research, "Versartis, Inc. operates as a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. The Company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 2a clinical trials for the treatment of growth hormone deficiency. Versartis, Inc. is headquartered in Redwood City, California. " (5/3/2017)
  • 2. Credit Suisse Group AG analysts commented, "We are incrementally more optimistic on the VSAR story following last week’s Investor Symposium given the progress the company is making for the well-discussed pediatric indication and also because of what may be an underappreciated opportunity in the adult indication. The stock has had a relatively volatile 12 months (along with much of SMID cap pharma/biotech), but as we start looking ahead to 2017 we see the company as potentially better positioned with the phase 3 data readout in pediatric growth hormone deficiency (GHD) that is expected in 3Q 2017 being the key value driver. The recent Teijen collaboration also puts VSAR in a more secure financial position to see things through on both the pediatric and adult side." (9/19/2016)

Are investors shorting Versartis?

Versartis saw a drop in short interest in April. As of April 13th, there was short interest totalling 865,144 shares, a drop of 9.6% from the March 31st total of 957,217 shares. Based on an average daily trading volume, of 233,763 shares, the short-interest ratio is currently 3.7 days.

Who are some of Versartis' key competitors?

Who owns Versartis stock?

Versartis' stock is owned by a number of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (12.59%), FMR LLC (11.12%), Aisling Capital LLC (5.78%), Sofinnova Management VIII L.L.C. (4.46%), Vanguard Group Inc. (2.86%) and Kingdon Capital Management L.L.C. (1.06%). Company insiders that own Versartis stock include Colin Hislop, Edmon R Jennings, Jay Shepard, John Varian, Joshua T Brumm, Paul Westberg, Perceptive Advisors Llc, R Scott Greer, Shahzad Malik, Shane Ward and Srinivas Akkaraju. View Institutional Ownership Trends for Versartis.

Who sold Versartis stock? Who is selling Versartis stock?

Versartis' stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Management VIII L.L.C., Aisling Capital LLC, FMR LLC, Kingdon Capital Management L.L.C., Morgan Stanley, Highbridge Capital Management LLC, SG Americas Securities LLC and ProShare Advisors LLC. Company insiders that have sold Versartis stock in the last year include Colin Hislop, Edmon R Jennings, Jay Shepard, John Varian, Joshua T Brumm, Paul Westberg, Shahzad Malik and Shane Ward. View Insider Buying and Selling for Versartis.

Who bought Versartis stock? Who is buying Versartis stock?

Versartis' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Driehaus Capital Management LLC, Renaissance Technologies LLC, ClariVest Asset Management LLC, Vanguard Group Inc., EcoR1 Capital LLC, Oxford Asset Management and Geode Capital Management LLC. Company insiders that have bought Versartis stock in the last two years include Joshua T Brumm, Perceptive Advisors Llc, R Scott Greer and Srinivas Akkaraju. View Insider Buying and Selling for Versartis.

How do I buy Versartis stock?

Shares of Versartis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Versartis stock cost?

One share of Versartis stock can currently be purchased for approximately $16.35.

Analyst Ratings

Consensus Ratings for Versartis (NASDAQ:VSAR) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.29 (60.77% upside)

Analysts' Ratings History for Versartis (NASDAQ:VSAR)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/4/2017Cantor FitzgeraldInitiated CoverageOverweight -> Overweight$34.00MediumView Rating Details
4/4/2017Piper Jaffray CompaniesBoost Price TargetOverweight$22.00 -> $26.00MediumView Rating Details
3/9/2017Barclays PLCInitiated CoverageOverweight -> Overweight$28.00LowView Rating Details
2/22/2017Canaccord GenuityReiterated RatingBuy$28.00N/AView Rating Details
12/20/2016Credit Suisse Group AGUpgradeNeutral -> Outperform$11.00 -> $20.00N/AView Rating Details
12/1/2016SunTrust Banks, Inc.Initiated CoverageBuy$25.00N/AView Rating Details
8/11/2016Citigroup IncSet Price TargetBuy$17.00 -> $23.00N/AView Rating Details
4/30/2016Morgan StanleyReiterated RatingHoldN/AView Rating Details
4/7/2016Northland SecuritiesInitiated CoverageOutperformN/AView Rating Details
2/2/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
(Data available from 5/22/2015 forward)


Earnings History for Versartis (NASDAQ:VSAR)
Earnings by Quarter for Versartis (NASDAQ:VSAR)
Earnings History by Quarter for Versartis (NASDAQ:VSAR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2017Q1 2017($0.71)($0.85)ViewN/AView Earnings Details
2/21/2017Q4 2016($0.62)($0.64)$10.00 millionViewN/AView Earnings Details
7/28/2016Q2($0.78)($0.75)ViewN/AView Earnings Details
2/18/2016Q415($0.71)($0.69)ViewN/AView Earnings Details
10/29/2015Q3($0.79)($0.69)ViewN/AView Earnings Details
8/4/2015Q2($0.64)($0.67)ViewN/AView Earnings Details
5/6/2015($0.70)($0.79)ViewN/AView Earnings Details
2/12/2015Q414($0.53)($0.65)ViewN/AView Earnings Details
11/6/2014Q3 14($0.46)($0.57)ViewN/AView Earnings Details
5/5/2014Q114($6.37)($2.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Versartis (NASDAQ:VSAR)
2017 EPS Consensus Estimate: ($2.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.79)($0.79)($0.79)
Q2 20171($0.83)($0.83)($0.83)
Q3 20171($0.81)($0.81)($0.81)
Q4 20171($0.40)($0.40)($0.40)
(Data provided by Zacks Investment Research)


Dividend History for Versartis (NASDAQ:VSAR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Versartis (NASDAQ:VSAR)
Insider Ownership Percentage: 11.60%
Institutional Ownership Percentage: 70.15%
Insider Trades by Quarter for Versartis (NASDAQ:VSAR)
Institutional Ownership by Quarter for Versartis (NASDAQ:VSAR)
Insider Trades by Quarter for Versartis (NASDAQ:VSAR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/16/2017Joshua T. BrummCFOSell1,263$17.40$21,976.20View SEC Filing  
4/19/2017Paul WestbergSVPSell1,316$19.85$26,122.60View SEC Filing  
4/4/2017Colin HislopInsiderSell35,000$21.20$742,000.00View SEC Filing  
3/24/2017Srinivas AkkarajuDirectorBuy571,429$12.25$7,000,005.25View SEC Filing  
3/17/2017Shahzad MalikDirectorSell483,670$18.11$8,759,263.70View SEC Filing  
3/15/2017Shahzad MalikDirectorSell166,330$19.09$3,175,239.70View SEC Filing  
3/15/2017Shane WardSVPSell2,041$19.01$38,799.41View SEC Filing  
2/27/2017Jay ShepardInsiderSell5,166$24.00$123,984.00View SEC Filing  
2/27/2017Paul WestbergSVPSell12,500$22.50$281,250.00View SEC Filing  
2/23/2017Jay ShepardInsiderSell16,000$19.25$308,000.00View SEC Filing  
2/23/2017Paul WestbergSVPSell25,000$18.75$468,750.00View SEC Filing  
2/13/2017Perceptive Advisors LlcMajor ShareholderBuy94,016$15.30$1,438,444.80View SEC Filing  
2/9/2017Perceptive Advisors LlcMajor ShareholderBuy145,823$13.72$2,000,691.56View SEC Filing  
2/3/2017Jay ShepardInsiderSell6,719$13.69$91,983.11View SEC Filing  
2/2/2017Jay ShepardInsiderSell24,211$13.77$333,385.47View SEC Filing  
1/30/2017Jay ShepardInsiderSell17,270$13.52$233,490.40View SEC Filing  
1/30/2017Joshua T BrummCFOSell2,945$13.85$40,788.25View SEC Filing  
1/30/2017Paul WestbergSVPSell1,916$13.85$26,536.60View SEC Filing  
1/11/2017Paul WestbergVPSell7,931$15.24$120,868.44View SEC Filing  
1/10/2017Paul WestbergVPSell11,213$15.66$175,595.58View SEC Filing  
1/9/2017Paul WestbergVPSell13,356$15.93$212,761.08View SEC Filing  
12/30/2016Perceptive Advisors LlcMajor ShareholderBuy94,750$14.66$1,389,035.00View SEC Filing  
12/29/2016Perceptive Advisors LlcMajor ShareholderBuy47,375$14.37$680,778.75View SEC Filing  
12/27/2016Joshua T BrummCFOSell990$15.85$15,691.50View SEC Filing  
12/27/2016Paul WestbergVPSell361$15.85$5,721.85View SEC Filing  
12/16/2016Paul WestbergVPSell5,000$15.00$75,000.00View SEC Filing  
12/8/2016Edmon R JenningsDirectorSell1,500$12.96$19,440.00View SEC Filing  
12/7/2016Joshua T BrummCFOSell3,021$13.25$40,028.25View SEC Filing  
10/3/2016Srinivas AkkarajuDirectorBuy571,429$12.25$7,000,005.25View SEC Filing  
8/25/2016John VarianDirectorSell1,600$12.97$20,752.00View SEC Filing  
8/22/2016Jay ShepardCEOSell5,442$12.88$70,092.96View SEC Filing  
6/15/2016Joshua T BrummCFOSell1,448$10.63$15,392.24View SEC Filing  
6/15/2016Paul WestbergVPSell725$10.63$7,706.75View SEC Filing  
5/20/2016Joshua T BrummCFOSell1,265$7.87$9,955.55View SEC Filing  
4/21/2016Paul WestbergVPSell1,430$9.68$13,842.40View SEC Filing  
12/30/2015Joshua T BrummCFOSell990$12.44$12,315.60View SEC Filing  
12/30/2015Paul WestbergVPSell362$12.44$4,503.28View SEC Filing  
11/12/2015Joshua T BrummCFOBuy2,500$9.99$24,975.00View SEC Filing  
11/11/2015R Scott GreerDirectorBuy10,000$10.17$101,700.00View SEC Filing  
7/6/2015Paul WestbergVPSell2,400$15.00$36,000.00View SEC Filing  
6/3/2015Paul WestbergVPSell2,400$16.73$40,152.00View SEC Filing  
5/4/2015Paul WestbergVPSell2,400$17.47$41,928.00View SEC Filing  
4/14/2015Jeffrey L ClelandCEOSell8,000$20.13$161,040.00View SEC Filing  
4/6/2015Paul WestbergVPSell2,400$17.49$41,976.00View SEC Filing  
3/23/2015Jeffrey L ClelandCEOSell4,000$20.26$81,040.00View SEC Filing  
3/20/2015Jeffrey L ClelandCEOSell3,179$20.03$63,675.37View SEC Filing  
3/10/2015Jeffrey L ClelandCEOSell4,000$20.23$80,920.00View SEC Filing  
3/2/2015Jeffrey L ClelandCEOSell2,871$20.11$57,735.81View SEC Filing  
2/3/2015Paul WestbergVPSell5,000$17.40$87,000.00View SEC Filing  
1/27/2015Aisling Capital Iii LpMajor ShareholderBuy145,000$17.25$2,501,250.00View SEC Filing  
1/27/2015R Scott GreerDirectorBuy5,500$17.25$94,875.00View SEC Filing  
1/22/2015Shahzad MalikDirectorBuy55,000$17.25$948,750.00View SEC Filing  
1/12/2015Jeffrey L ClelandCEOSell4,000$22.85$91,400.00View SEC Filing  
1/5/2015Jeffrey L ClelandCEOSell4,000$21.94$87,760.00View SEC Filing  
1/5/2015Paul WestbergVPSell5,000$22.48$112,400.00View SEC Filing  
12/29/2014Jeffrey L ClelandCEOSell4,000$22.11$88,440.00View SEC Filing  
12/22/2014Jeffrey L ClelandCEOSell8,000$21.14$169,120.00View SEC Filing  
12/18/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell150,000$19.01$2,851,500.00View SEC Filing  
12/12/2014Paul WestbergVPSell10,000$18.55$185,500.00View SEC Filing  
11/24/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell17,207$18.02$310,070.14View SEC Filing  
11/21/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell26,793$18.04$483,345.72View SEC Filing  
11/20/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell9,000$18.32$164,880.00View SEC Filing  
11/18/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell191,362$19.38$3,708,595.56View SEC Filing  
11/13/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell12,438$19.43$241,670.34View SEC Filing  
11/12/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell36,200$19.42$703,004.00View SEC Filing  
9/29/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell12,556$20.02$251,371.12View SEC Filing  
3/27/2014Leaf Ventures Ii L.P. NewDirectorBuy60,000$21.02$1,261,200.00View SEC Filing  
3/26/2014Aisling Capital Iii LpMajor ShareholderBuy60,000$21.00$1,260,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Versartis (NASDAQ:VSAR)
Latest Headlines for Versartis (NASDAQ:VSAR)
DateHeadline logoInsider Selling: Versartis Inc (VSAR) CFO Sells 1,263 Shares of Stock - May 17 at 8:35 PM logoVersartis Inc Expected to Post FY2017 Earnings of ($3.29) Per Share (VSAR) - May 12 at 11:44 AM logoShort Interest in Versartis Inc (VSAR) Declines By 9.6% - May 10 at 7:16 AM logoVersartis Inc (VSAR) Now Covered by Cantor Fitzgerald - May 4 at 7:40 PM logoVersartis (VSAR) Receives News Sentiment Score of -0.12 - May 2 at 1:18 PM logoVersartis Inc (VSAR) Expected to Announce Earnings of -$0.78 Per Share - May 1 at 7:48 PM logoFY2021 EPS Estimates for Versartis Inc (VSAR) Lifted by Analyst - May 1 at 3:06 PM logoVersartis Inc (VSAR) Given Average Rating of "Buy" by Brokerages - May 1 at 10:38 AM logoSomewhat Critical Press Coverage Unlikely to Impact Versartis (VSAR) Share Price - April 29 at 8:18 AM logoVersartis Inc (VSAR) Posts Earnings Results, Misses Estimates By $0.14 EPS - April 28 at 1:03 AM logoVersartis Inc (VSAR) Issues Earnings Results - April 27 at 11:18 PM logoVersartis Reports First Quarter 2017 Financial Results - April 27 at 11:05 PM logoVersartis reports 1Q loss - April 27 at 6:16 PM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Versartis Inc. - VSAR - April 26 at 5:10 PM logoVersartis (VSAR) Given Daily Media Sentiment Score of 0.27 - April 26 at 10:15 AM logoVersartis Appoints Jay Stout, Ph.D., as Senior Vice President, Technical Operations - April 25 at 8:45 AM logoVersartis (VSAR) Earns Media Sentiment Score of 0.31 - April 23 at 12:37 PM logoVersartis Inc (VSAR) SVP Sells $26,122.60 in Stock - April 20 at 8:10 PM logoVersartis Inc (VSAR) Expected to Post Quarterly Sales of $0.00 - April 12 at 12:11 PM logoVersartis Reports New Data on Long-Acting Somavaratan in Growth Hormone Deficiency at ENDO 2017 - April 10 at 8:26 AM logoInsider Selling: Versartis Inc (VSAR) Insider Sells 35,000 Shares of Stock - April 5 at 8:01 PM logoPiper Jaffray Companies Reaffirms "Overweight" Rating for Versartis Inc (VSAR) - April 4 at 10:33 PM logoVersartis Inc (VSAR) Receives Average Recommendation of "Buy" from Brokerages - April 4 at 12:31 PM logoVersartis Announces Three Year Somavaratan Data at ENDO 2017 Showing Safety and Efficacy in Line with Historical U.S. Daily rhGH Data in Pediatric GHD - April 3 at 8:41 PM logoVERSARTIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits - April 3 at 8:41 PM logoInsider Invests in Versartis - March 30 at 8:20 PM logoInsider Buying: Versartis Inc (VSAR) Director Buys 571,429 Shares of Stock - March 29 at 9:10 AM logoVERSARTIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obliga - March 23 at 8:55 PM logoVersartis to Host Conference Call to Review Data from ENDO 2017 on Long-Acting Somavaratan for Growth Hormone Deficiency - March 23 at 3:54 PM logoVersartis Appoints Tracy Woody as Chief Commercial Officer - March 16 at 6:31 AM logoVERSARTIS, INC. Files SEC form 10-K, Annual Report - March 10 at 9:15 AM logoBarclays Sees 40% Upside In Versartis Over Next Year - March 9 at 11:54 PM logoVersartis Announces Data on Long-Acting Somavaratan for Growth Hormone Deficiency to be Featured in Late-Breaker Presentation at ENDO 2017 - March 3 at 5:57 AM logoVersartis to Present at Cowen & Co. Annual Healthcare Conference and Barclays Global Healthcare Conference - March 2 at 1:24 AM logoCompany Spotlight: Versartis - February 25 at 8:06 PM logo[$$] The Length of a Biotech Patent's Life, Corrected - February 25 at 4:18 AM logoVERSARTIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - February 23 at 3:21 AM logoVersartis Reports Fourth Quarter 2016 Financial Results - February 21 at 4:07 PM logo[$$] Why Biotech Looks Like a Good Bet in 2017 - February 18 at 11:23 AM logoTwitter Is One of Five Stocks Insiders Really Love Right Now - February 17 at 6:59 AM logoVersartis (VSAR) Names Joshua T. Brumm as COO - February 1 at 7:20 AM logo2:43 am Versartis to present Growth Hormone Deficiency update at Endo; shows consistent safety results over 3 years - February 1 at 7:20 AM logoVersartis Promotes Joshua T. Brumm to Chief Operating Officer and Paul Westberg to Chief Business Officer - February 1 at 7:20 AM logoVersartis’ Long-Acting Somavaratan for Growth Hormone Deficiency to be Featured in Multiple Oral and Poster Presentations at ENDO 2017 - January 30 at 9:14 PM logoHighlighting Biotech's Versartis' Potential - January 24 at 3:24 PM logoVersartis (VSAR) Shares March Higher, Can It Continue? - January 6 at 6:30 AM logoCoverage initiated on Versartis by SunTrust - December 2 at 8:10 PM logoVersartis, Inc. :VSAR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 - November 29 at 1:07 PM logoVERSARTIS, INC. Financials - November 10 at 8:19 PM logoVersartis Presents Safety, Efficacy and IGF-I Data for Somavaratan in Pediatric Growth Hormone Deficiency at the 2016 Congress of the GRS & IGF Society - November 10 at 11:59 AM


Versartis (VSAR) Chart for Monday, May, 22, 2017

This page was last updated on 5/22/2017 by Staff